Literature DB >> 16422002

Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy.

Hatice Canataroglu1, Ilter Varinli, Altan A Ozcan, Abdullah Canataroglu, Figen Doran, Seyhan Varinli.   

Abstract

PURPOSE: To investigate the interleukin (IL)-6 levels, IL-8 levels, and cellular composition of the vitreous humor in patients with proliferative diabetic retinopathy (PDR), proliferative vitreoretinopathy (PVR), and traumatic PVR.
METHODS: Vitreous samples from 14 patients with PDR, 10 patients with PVR, and 10 patients with traumatic PVR were analyzed. Fifteen cadaver eyes were used as controls. Cytokine levels were measured by ELISA.
RESULTS: Elevated IL-6 levels were detected in the vitreous of 12 (85.7%) of the PDR patients, eight (80%) of the PVR patients, and all (100%) of the traumatic PVR patients. None of the control IL-6 results were elevated. Vitreous IL-8 levels were elevated in 12 (85.7%) of the PDR patients, six (60%) of the PVR patients, all (100%) of the traumatic PVR patients, and one (6.7%) of the control eyes. Cytological examination of the vitreous specimens revealed a predominance of macrophages (50%) in the PDR samples and a predominance of retinal pigment epithelial (RPE) cells (60%) in the PVR samples. In contrast, neutrophils predominated (88%) in the traumatic PVR samples.
CONCLUSION: The findings suggest that IL-6 and IL-8 may be involved in the pathogenesis of PDR, PVR, and traumatic PVR. High proportions of RPE cells and macrophages are associated with elevated IL-6 and IL-8 levels in the vitreous of PDR and PVR patients; however, the fact that these cells are not predominant in traumatic PVR suggests that different immune response mechanisms may be active in the pathogenesis of these disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16422002     DOI: 10.1080/09273940490518900

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  32 in total

1.  Hypoxia and inflammation in the release of VEGF and interleukins from human retinal pigment epithelial cells.

Authors:  Olli Arjamaa; Vesa Aaltonen; Niina Piippo; Tamás Csont; Goran Petrovski; Kai Kaarniranta; Anu Kauppinen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-19       Impact factor: 3.117

Review 2.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

3.  Control of chemokine gradients by the retinal pigment epithelium.

Authors:  Guangpu Shi; Arvydas Maminishkis; Tina Banzon; Stephen Jalickee; Rong Li; Jeffrey Hammer; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

Review 4.  The role of inflammation in diabetic eye disease.

Authors:  Marina Mesquida; Faye Drawnel; Sascha Fauser
Journal:  Semin Immunopathol       Date:  2019-06-07       Impact factor: 9.623

5.  Neutrophils compromise retinal pigment epithelial barrier integrity.

Authors:  Jiehao Zhou; Shikun He; Ning Zhang; Christine Spee; Peng Zhou; Stephen J Ryan; Ram Kannan; David R Hinton
Journal:  J Biomed Biotechnol       Date:  2010-03-03

6.  Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses.

Authors:  Steven Pennock; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2012-03-19       Impact factor: 4.272

7.  A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Authors:  Steven Pennock; Marc-Andre Rheaume; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2011-10-28       Impact factor: 4.307

8.  miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions.

Authors:  Eun-Ah Ye; Jena J Steinle
Journal:  Vision Res       Date:  2017-04-26       Impact factor: 1.886

9.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

10.  Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.

Authors:  Shikun He; S Ram Kumar; Peng Zhou; Valery Krasnoperov; Stephen J Ryan; Parkash S Gill; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.